AGY Allergy Therapeutics plc

0.0161USD1.225 GBp · LSE-12.50%Mkt Cap: 102.02M USDP/E: —

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally.…

Key Statistics

Company
Market Cap102.02M USD
Enterprise Value156.52M USD
Revenue (TTM)78.74M USD
Gross Profit38.54M USD
Net Income (TTM)-52.78M USD
Revenue/Share0.01 USD
Last Price0.0161 USD
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees—
CountryGB
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINGB00B02LCQ05
Valuation
P/E (Trailing)—
P/E (Forward)-1.70
PEG—
EV/EBITDA-3.59
EV/Revenue1.99
P/S1.30
P/B-6.13
EPS (TTM)-0.01 USD
EPS (Forward)-0.0095 USD
52W Range
0.000010% of range0.1591
52W High0.1591 USD
52W Low0.0000 USD
Profitability
Gross Margin53.23%
Oper. Margin-63.17%
EBITDA Margin-55.41%
Profit Margin-72.91%
ROE142.35%
ROA-59.42%
ROIC-145.87%
ROCE-69.79%
Growth
Revenue Growth12.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-36.97M USD
CapEx (TTM)4.50M USD
FCF Margin-65.63%
FCF Yield-50.65%
Net Debt56.28M USD
Net Debt/EBITDA-1.29
Net Debt/FCF—
Balance Sheet
Debt/Equity-2.13
Current Ratio2.29
Quick Ratio1.61
Book Value/Sh-0.0026 USD
Cash/Share0.0053 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)0.1710 USD
Upside (mean)+961.2%
Target Range0.1710 USD – 0.1710 USD
# Analysts1
Ownership
Shares Out.6.33B
Float711.19M
Insiders88.78%
Institutions0.01%
Technical
SMA 500.0507 (-68.2%)
SMA 2000.0967 (-83.3%)
Beta—
S&P 52W Chg12.00%
Avg Vol (30d)1.65M
Avg Vol (10d)2.14M
Technical Indicators
RSI (14)9.9
MACD-0.8197
MACD Signal-0.8225
MACD Hist.+0.0028
BB Upper0.0656 USD
BB Middle0.0305 USD
BB Lower-0.0045 USD
BB Width229.64%
ATR (14)0.0045 USD
Vol Ratio (20d)4.48x

About Allergy Therapeutics (LON: AGY)

›

Allergy Therapeutics (LON: AGY) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector.

The shares were at 1.225 GBp on 19 November 2026, down 86.2% over 52 weeks.

Its market capitalisation is 77.57M GBP.

Allergy Therapeutics reports return on equity of 142.3%, an operating margin of -63.2% and revenue up 12.3% year over year.

Its debt exceeds its cash by 42.79M GBP. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.